Medtronic (NYSE:MDT) said today that its Envision Pro continuous glucose monitoring system received CE Mark approval and will be commercialized in Europe and the Middle East this fall.

The Envision Pro CGM is designed to provide blinded glucose levels, track events and compile reports for physicians to assess therapies. The CGM collects glucose data to generate up to five diagnostic reports, including the Pattern Snapshot, which is designed to identify patterns of high and low sugar levels and their association with food, medication, exercise and sleep. It does not require finger-stick calibration and communicates wirelessly with the patient’s smartphone.

Get the full story at our sister site, Drug Delivery Business News.